Hengqin team can spot cancer years ahead of danger

Zhuhai Hopegenes Medical & Pharmaceutical Institute has announced technologies that can detect 27 types of cancers five to seven years in advance with an accuracy rate of 99.3 percent.

At a press conference on Oct 28, the company unveiled two high-end cancer detection technologies that can trace associated ENOX2, a splice variant found on the cell surface of human cancers; and DNA methylation, a process that can change the healthy regulation of gene expression into a disease pattern.

Also announced was the CAR-T cell immunotherapy by which doctors will be able to pinpoint a cancer tumor and reverse the disease through early intervention with a success rate of 95 to 96 percent.

Hopegenes was established by a group of life technology and bio-pharmaceutical experts who returned to China from the US and Europe. The company is listed on National Equities Exchange and Quotations (NEEQ), nicknamed "The New Third Board".

As a strategic partner of the Hengqin International Intellectual Property Rights Exchange (HIPEX) National Platform, the company employs 300 experts from home and abroad. It has five branches and several holding companies in the country plus eight research institutions and cooperative labs overseas.

Hengqin Free Trade Zone [Photo by Li Jiandong / Zhuhai Daily]